C Hocke1, P Morlat, G Chene, L Dequae, F Dabis. 1. Service de Gynécologie-Obstétrique, Hôpital Pellegrin, Centre Hospitalier Universitaire, Bordeaux, France.
Abstract
OBJECTIVE: To study the prognostic role of pregnancy on the progression of human immunodeficiency virus (HIV) infection. METHODS: In a prospective cohort study at the Bordeaux University Hospital, France, 57 women who completed a pregnancy during the course of their HIV infection were compared with 114 HIV-infected women who never conceived. The two groups were matched on CD4 lymphocyte count (CD4), age, and year of HIV diagnosis. The main outcome measures were death, occurrence of a first AIDS-defining event, and drop of the CD4 below 200/mm3. RESULTS: The mean follow-up period in pregnant women was 61 months from HIV diagnosis (median CD4 at entry 455/mm3) and 54 months from beginning of pregnancy. Nonpregnant women were followed-up for 50 months since HIV diagnosis (median CD4 460/mm3). The proportion of asymptomatic women at entry in the study was 51 of 57 (90%) in pregnant and 87 of 114 (76%) in nonpregnant women. No significant difference was observed between the two groups with regard to the different end points studied, even after adjustment for other prognostic variables. Adjusted hazard ratios (pregnant/nonpregnant) were 0.92 for death (95% confidence interval [CI] 0.40-2.12), 1.02 for occurrence of a first AIDS-defining event (95% CI 0.48-2.18), and 1.20 for drop of the CD4 to less than 200/mm3 (95% CI 0.63-2.27). CONCLUSION: In a cohort of HIV-infected women with mild to moderate immunosuppression, pregnancy did not accelerate progression to AIDS or death.
OBJECTIVE: To study the prognostic role of pregnancy on the progression of human immunodeficiency virus (HIV) infection. METHODS: In a prospective cohort study at the Bordeaux University Hospital, France, 57 women who completed a pregnancy during the course of their HIV infection were compared with 114 HIV-infectedwomen who never conceived. The two groups were matched on CD4 lymphocyte count (CD4), age, and year of HIV diagnosis. The main outcome measures were death, occurrence of a first AIDS-defining event, and drop of the CD4 below 200/mm3. RESULTS: The mean follow-up period in pregnant women was 61 months from HIV diagnosis (median CD4 at entry 455/mm3) and 54 months from beginning of pregnancy. Nonpregnant women were followed-up for 50 months since HIV diagnosis (median CD4 460/mm3). The proportion of asymptomatic women at entry in the study was 51 of 57 (90%) in pregnant and 87 of 114 (76%) in nonpregnant women. No significant difference was observed between the two groups with regard to the different end points studied, even after adjustment for other prognostic variables. Adjusted hazard ratios (pregnant/nonpregnant) were 0.92 for death (95% confidence interval [CI] 0.40-2.12), 1.02 for occurrence of a first AIDS-defining event (95% CI 0.48-2.18), and 1.20 for drop of the CD4 to less than 200/mm3 (95% CI 0.63-2.27). CONCLUSION: In a cohort of HIV-infectedwomen with mild to moderate immunosuppression, pregnancy did not accelerate progression to AIDS or death.
Authors: L M Koonin; T V Ellerbrock; H K Atrash; M F Rogers; J C Smith; C J Hogue; M A Harris; W Chavkin; A L Parker; G J Halpin Journal: JAMA Date: 1989-03-03 Impact factor: 56.272
Authors: P A Selwyn; E E Schoenbaum; K Davenny; V J Robertson; A R Feingold; J F Shulman; M M Mayers; R S Klein; G H Friedland; M F Rogers Journal: JAMA Date: 1989-03-03 Impact factor: 56.272
Authors: M M Deschamps; J W Pape; M Desvarieux; P Williams-Russo; S Madhavan; J L Ho; W D Johnson Journal: J Acquir Immune Defic Syndr (1988) Date: 1993-05
Authors: P Morlat; P Parneix; D Douard; D Lacoste; M Dupon; G Chêne; J L Pellegrin; J M Ragnaud; F Dabis Journal: AIDS Date: 1992-10 Impact factor: 4.177
Authors: A R Moss; P Bacchetti; D Osmond; W Krampf; R E Chaisson; D Stites; J Wilber; J P Allain; J Carlson Journal: Br Med J (Clin Res Ed) Date: 1988-03-12
Authors: Jose H Pilotto; Luciane S Velasque; Ruth K Friedman; Ronaldo I Moreira; Valdilea G Veloso; Beatriz Grinsztejn; Mariza G Morgado; D Heather Watts; Judith S Currier; Risa M Hoffman Journal: Antivir Ther Date: 2011
Authors: M C Zink; A M Amedee; J L Mankowski; L Craig; P Didier; D L Carter; A Muñoz; M Murphey-Corb; J E Clements Journal: Am J Pathol Date: 1997-09 Impact factor: 4.307
Authors: Beverly E Sha; Camlin Tierney; Susan E Cohn; Xin Sun; Robert W Coombs; Lisa M Frenkel; Spyros A Kalams; Francesca T Aweeka; Barbara Bastow; Arlene Bardeguez; Anne Kmack; Alice Stek Journal: HIV Clin Trials Date: 2011 Jan-Feb
Authors: V Le Moing; A Taïeb; P Longuet; C Lewden; V Delcey; M C Thiebaut Drobacheff; G Chêne; C Leport Journal: HIV Med Date: 2008-09-14 Impact factor: 3.180
Authors: Vlada V Melekhin; Bryan E Shepherd; Samuel E Stinnette; Peter F Rebeiro; Gema Barkanic; Stephen P Raffanti; Timothy R Sterling Journal: PLoS One Date: 2009-09-09 Impact factor: 3.240
Authors: Akinsegun A Akinbami; Abidoye Gbadegesin; Sarah O Ajibola; Ebele I Uche; Adedoyin O Dosunmu; Adewumi Adediran; Adekunle Sobande Journal: HIV AIDS (Auckl) Date: 2015-04-10